Group 1 - The company, Junshi Biosciences, announced the approval of multiple proposals during the ninth meeting of its fourth supervisory board, including a proposal to grant stock options to a director and major shareholder [2] - The announcement was made on the evening of September 2 [2] - The proposals are part of the company's ongoing governance and incentive strategies [2]

Core Viewpoint - Junshi Biosciences announced the approval of multiple proposals during the 11th meeting of its fourth board of directors, including a proposal to grant stock options to a director and major shareholder [2] Group 1 - The board meeting was held on September 2, where significant resolutions were made [2] - The proposal regarding stock options is aimed at aligning the interests of the director with those of the shareholders [2]

Group 1 - The core point of the article is that Junshi Biosciences announced the approval of a clinical trial application for its drug JT118 injection by the National Medical Products Administration [1] Group 2 - The approval was granted to Junshi's subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd [1] - The announcement was made on the evening of September 2 [1]

Group 1: 恒瑞医药 - Company received approval for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor [1] - Subsidiary received approval for SHR-A2009, an antibody-drug conjugate targeting HER3 [1] - Company was established in April 1997, focusing on drug research, production, and sales [1] Group 2: 康德莱 - Controlling shareholder plans to transfer 5% of shares to strategic investor at a price of 10.81 yuan per share, totaling 236 million yuan [1] - Post-transfer, controlling shareholder's stake will decrease from 39.58% to 34.58% [1] - Company was established in July 1998, specializing in medical devices [2] Group 3: 中钢洛耐 - Shareholder plans to reduce holdings by up to 1% of total shares due to fund exit needs [3] - Company was established in August 2006, focusing on high-end refractory materials [3] Group 4: 瑞玛精密 - Subsidiary completed acquisition of land in Mexico for production operations, covering 52,300 square meters at a price of 3.4064 million USD [4] - Company was established in March 2012, specializing in precision metal stamping and related products [4] Group 5: 鸿博股份 - Company confirmed normal operations despite stock price fluctuations exceeding 20% over three trading days [5] - Company was established in June 1999, focusing on lottery services and high-end packaging [6] Group 6: 东芯股份 - Company completed stock trading risk investigation and resumed trading [7] - Company was established in November 2014, specializing in storage chip design and sales [7] Group 7: 凯迪股份 - Company stated that its robot products are still in development and will not generate revenue in the short term [8] - Company was established in August 1992, focusing on linear drive systems [8] Group 8: 诺唯赞 - Major shareholder plans to reduce holdings by up to 3% due to funding needs [9] - Company was established in March 2012, focusing on functional proteins and organic materials [9] Group 9: 君实生物 - Company received approval for clinical trials of JT118 injection, a "two-in-one" recombinant protein vaccine for monkeypox [10] - Company was established in December 2012, focusing on new drug research and related services [10] Group 10: 赛力斯 - Company reported August sales of 45,818 vehicles, with a 19.57% increase in new energy vehicle sales [11] - Company was established in September 2012, focusing on automotive research and sales [11] Group 11: 燕东微 - Major shareholder plans to reduce holdings by up to 1% due to management needs [13] - Company was established in October 1987, focusing on semiconductor products and services [13] Group 12: 中百集团 - Company reported cumulative litigation and arbitration amounts of approximately 262 million yuan over the past 12 months [14] - Company was established in January 1990, focusing on retail business [14] Group 13: 金开新能 - Company received 939 million yuan in renewable energy subsidies, with a 341.67% increase year-on-year [15] - Company was established in March 1997, focusing on renewable energy development and operation [15] Group 14: *ST天茂 - Company plans to terminate stock listing and initiate cash option mechanism for shareholders [16] - Company was established in November 1993, focusing on various insurance services [16] Group 15: 宁德时代 - Company repurchased 8.69 million A-shares for a total of 2.131 billion yuan [17] - Company was established in December 2011, focusing on battery research and production [17] Group 16: 山西高速 - Controlling shareholder plans to increase holdings by 30 to 60 million yuan [18] - Company was established in February 1996, focusing on highway management [18] Group 17: 青岛银行 - Major shareholder plans to increase holdings by 233 to 291 million shares [19] - Company was established in November 1996, focusing on banking services [19] Group 18: 格力电器 - Major shareholder completed share increase of 46.38 million shares for 2.099 billion yuan [20] - Company was established in December 1989, focusing on air conditioning production and sales [20] Group 19: 中国石油 - Company plans to transfer 541 million A-shares to China Mobile Group to enhance strategic cooperation [21] - Company was established in November 1999, focusing on oil and gas exploration and production [21] Group 20: 镇洋发展 - Company announced a merger plan with Zhejiang Huhangyong Highway Co., with a share exchange ratio of 1:1.08 [22] - Company was established in December 2004, focusing on chemical products [22]

Market Overview - The market experienced fluctuations with the ChiNext index leading the decline, while the total trading volume in the Shanghai and Shenzhen markets reached 2.87 trillion yuan, an increase of 125 billion yuan compared to the previous trading day [1] - Over 4,000 stocks in the market saw declines, with sectors such as banking, precious metals, robotics, and oil showing the most significant gains [1] Industry News - The "High-Quality Standard System Construction Plan for Industrial Mother Machines" was officially issued by two departments, leading to a surge in the industrial mother machine concept stocks, with companies like Hengjin Induction, Huadong CNC, and Bojie Shares hitting the daily limit [1] - The robotics sector also experienced a boost from this news, with Zhejiang Rongtai reaching a historical high and other companies like Top Group, Longxi Shares, and Qin Chuan Machine Tool also hitting the daily limit [1] Company Updates - Kedi Shares announced that its robotics-related business is still in the development stage and will not generate revenue in the short term, which is not expected to significantly impact the company's performance [2] - Seres reported that its August new energy vehicle production reached 43,069 units, a year-on-year increase of 19.38%, while sales were 43,262 units, up 19.57% year-on-year [3] - Junshi Biosciences received approval for clinical trials of its JT118 injection, a "two-in-one" recombinant protein vaccine aimed at preventing monkeypox virus infection, marking a significant development as no such vaccine has been approved in China yet [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） (1)建議採納2025年H股股票期權激勵計劃； (2)建議向承授人授予H股股票期權； (3)建議採納2025年A股股票期權激勵計劃；及 (4)建議向一名董事兼主要股東授予A股股票期權 建議採納2025年H股股票期權激勵計劃和2025年A股股票期權激勵計劃 於2025年9月2日，董事會已審議及批准（其中包括）(i)建議採納2025年H股股票 期權激勵計劃；及(ii)採納2025年A股股票期權激勵計劃。根據上市規則第十七 章，2025年H股股票期權激勵計劃及2025年A股股票期權激勵計劃將構成本公 司涉及發行新股份的股份計劃，因此採納2025年H股股票期權激勵計劃及2025 年A股股票期權激勵計劃須獲股東批准。 建議向承授人授予及 ...

Core Viewpoint - Junshi Biosciences (01877) announced the approval of the 2025 H-share and A-share stock option incentive plans by the board of directors, which require shareholder approval due to the issuance of new shares [1] Group 1: Stock Option Incentive Plans - The board has approved the proposal to adopt the 2025 H-share stock option incentive plan and the 2025 A-share stock option incentive plan [1] - The 2025 H-share stock option incentive plan includes the granting of 13.21 million H-share stock options to seven executive directors and three other employee participants [1] - The 2025 A-share stock option incentive plan proposes granting 8 million A-share stock options to Mr. Xiong, contingent upon the adoption of the respective plans [1]

董事会已审议及批准(其中包括)(i)建议向七名执行董事(包括李宁博士、邹建军博士、李聪先生、张卓兵 先生、姚盛博士、王刚博士、李鑫博士)及其余三名雇员参与者授予1321万份H股股票期权;及(ii)建议向 熊先生授予800万份A股股票期权，均须待2025年A股股票期权激励计划和2025年H股股票期权激励计划 采纳后生效。 智通财经APP讯，君实生物(01877)发布公告，于2025年9月2日，董事会已审议及批准(其中包括)(i)建议 采纳2025年H股股票期权激励计划;及(ii)采纳2025年A股股票期权激励计划。根据上市规则第十七章， 2025年H股股票期权激励计划及2025年A股股票期权激励计划将构成公司涉及发行新股份的股份计划， 因此采纳2025年H股股票期权激励计划及2025年A股股票期权激励计划须获股东批准。 ...

格隆汇9月2日丨君实生物(01877.HK)公告，于2025年9月2日，董事会已审议及批准(其中包括)(i)建议采 纳2025年H股股票期权激励计划；及(ii)采纳2025年A股股票期权激励计划。根据上市规则第十七章， 2025年H股股票期权激励计划及2025年A股股票期权激励计划将构成公司涉及发行新股份的股份计划， 因此采纳2025年H股股票期权激励计划及2025年A股股票期权激励计划须获股东批准。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 建議採納2025年H股股票期權激勵計劃和2025年A股股票期權激勵計劃 於2025年9月2日，董事會已審議及批准（其中包括）(i)建議採納2025年H股股票 期權激勵計劃；及(ii)採納2025年A股股票期權激勵計劃。根據上市規則第十七 章，2025年H股股票期權激勵計劃及2025年A股股票期權激勵計劃將構成本公 司涉及發行新股份的股份計劃，因此採納2025年H股股票期權激勵計劃及2025 年A股股票期權激勵計劃須獲股東批准。 建議向承授人授予及建議向熊先生授予 董事會已審議及批准（其中包括）(i)建議向七名執行董事（包括李寧博士、鄒建 軍博士、李聰先生、張卓兵先生、姚盛博士、王剛博士、李鑫博士）及其餘三名 僱員參與者授予13 ...